Skip Navigation


Human Molecular Genetics Advance Access originally published online on August 19, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
12/suppl_2/R135    most recent
ddg278v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by McGregor, E.
Right arrow Articles by Dunn, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGregor, E.
Right arrow Articles by Dunn, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2003, Vol. 12, Review Issue 2 R135-R144
DOI: 10.1093/hmg/ddg278
© 2003 Oxford University Press

Proteomics of heart disease

Emma McGregor1 and Michael J. Dunn2,*

1Proteome Sciences plc and 2Department of Neuroscience, Institute of Psychiatry, Kings College, London SE5 8AF, UK

Received July 3, 2003; Accepted August 11, 2003

Heart diseases resulting in heart failure are among the leading causes of morbidity and mortality in developed countries. The underlying molecular causes of cardiac dysfunction in most heart diseases are still largely unknown, but are likely to result from underlying alterations in gene and protein expression. Proteomics now allows us to examine global alterations in protein expression in the diseased heart and will provide new insights into cellular mechanisms involved in cardiac dysfunction and should also result in the generation of new diagnostic and therapeutic markers. In this article we review the current status of proteomic technologies and describe how these are being applied to studies of human heart disease.

* To whom correspondence should be addressed at: Department of Neuroscience, P045, Institute of Psychiatry, Kings College, University of London, De Crespigny Park, London SE5 8AF, UK. Tel: +44 2078485110; Fax: +44 2078485109; Email: m.dunn{at}iop.kcl.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. ProteomicsHome page
A. O. Gramolini, T. Kislinger, R. Alikhani-Koopaei, V. Fong, N. J. Thompson, R. Isserlin, P. Sharma, G. Y. Oudit, M. G. Trivieri, A. Fagan, et al.
Comparative Proteomics Profiling of a Phospholamban Mutant Mouse Model of Dilated Cardiomyopathy Reveals Progressive Intracellular Stress Responses
Mol. Cell. Proteomics, March 1, 2008; 7(3): 519 - 533.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. S. Vasan
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Circulation, May 16, 2006; 113(19): 2335 - 2362.
[Full Text] [PDF]

Home page
 Circ. Res.Home page
E. McGregor and M. J. Dunn
Proteomics of the Heart: Unraveling Disease
Circ. Res., February 17, 2006; 98(3): 309 - 321.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. Mayr, R. Siow, Y.-L. Chung, U. Mayr, J. R. Griffiths, and Q. Xu
Proteomic and Metabolomic Analysis of Vascular Smooth Muscle Cells: Role of PKC{delta}
Circ. Res., May 28, 2004; 94(10): e87 - e96.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.